Latest News

FDA Approves Biosimilar Ustekinumab-ttwe for All Indications of Reference Medicine
FDA Approves Biosimilar Ustekinumab-ttwe for All Indications of Reference Medicine

July 1st 2024

Pyzchiva will be commercialized by Sandoz in the United States.

AbbVie Unveils Promising 148-Week VALUE Trial Data for Risankizumab at IFPA Conference
AbbVie Unveils Promising 148-Week VALUE Trial Data for Risankizumab at IFPA Conference

June 28th 2024

Validation of Improved QoL Assessment for Moderate Psoriasis
Validation of Improved QoL Assessment for Moderate Psoriasis

June 27th 2024

SFA-002 Shows Promise in Early Clinical Trial Psoriasis Cohorts
SFA-002 Shows Promise in Early Clinical Trial Psoriasis Cohorts

June 20th 2024

Psoriasis and Sunburn: New Study Highlights Increased Risk and Clinical Implications
Psoriasis and Sunburn: New Study Highlights Increased Risk and Clinical Implications

June 18th 2024

More News

© 2024 MJH Life Sciences

All rights reserved.